3,4-二氨基吡啶（DAP）治疗兰伯特-伊顿肌无力综合征（LEMS）。 - Suppr

Suppr

超能文献

3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

作者信息

Sanders D B

机构信息

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

Ann N Y Acad Sci. 1998 May 13;841:811-6. doi: 10.1111/j.1749-6632.1998.tb11022.x.

DOI:10.1111/j.1749-6632.1998.tb11022.x

PMID:9668334

Abstract

摘要

相似文献

3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).3,4-二氨基吡啶（DAP）治疗兰伯特-伊顿肌无力综合征（LEMS）。

Ann N Y Acad Sci. 1998 May 13;841:811-6. doi: 10.1111/j.1749-6632.1998.tb11022.x.

3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.3,4-二氨基吡啶治疗兰伯特-伊顿肌无力综合征和重症肌无力。

Ann N Y Acad Sci. 1993 Jun 21;681:588-90. doi: 10.1111/j.1749-6632.1993.tb22949.x.

[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].

Med Clin (Barc). 1996 Jan 13;106(1):37-8.

3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.3,4-二氨基吡啶，一种孤儿药，用于兰伯特-伊顿肌无力综合征的对症治疗。

Pflugers Arch. 1996;431(6 Suppl 2):R295-6. doi: 10.1007/BF02346385.

3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.用于治疗具有兰伯特-伊顿肌无力综合征电生理模式的重症肌无力的3,4-二氨基吡啶

J Clin Neurosci. 2018 Apr;50:194-198. doi: 10.1016/j.jocn.2018.01.024. Epub 2018 Feb 19.

3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.3,4-二氨基吡啶治疗成人兰伯特-伊顿肌无力综合征：随机对照试验的荟萃分析

BMC Neurol. 2021 Sep 25;21(1):371. doi: 10.1186/s12883-021-02405-3.

Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.兰伯特-伊顿肌无力综合征中的急性通气衰竭及其对3,4-二氨基吡啶的反应。

Neurology. 1996 Apr;46(4):1143-5. doi: 10.1212/wnl.46.4.1143.

Treatment for Lambert-Eaton myasthenic syndrome.兰伯特-伊顿肌无力综合征的治疗。

Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD003279. doi: 10.1002/14651858.CD003279.pub3.

Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.磷酸阿米芬啶（Firdapse(®)）在一项针对兰伯特-伊顿肌无力综合征的3期临床试验中有效且安全。

Muscle Nerve. 2016 May;53(5):717-25. doi: 10.1002/mus.25070. Epub 2016 Mar 3.

Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.3,4-二氨基吡啶治疗前后兰伯特-伊顿肌无力综合征的刺激单纤维肌电图

Muscle Nerve. 1997 Jun;20(6):735-9. doi: 10.1002/(sici)1097-4598(199706)20:6<735::aid-mus11>3.0.co;2-t.

引用本文的文献

Downbeat Nystagmus: Case Report, Updated Review, Therapeutics, and Neurorehabilitation.下跳性眼球震颤：病例报告、最新综述、治疗方法及神经康复

Brain Sci. 2025 Aug 13;15(8):859. doi: 10.3390/brainsci15080859.

Foodborne botulism outbreak with potential new management options.食源性肉毒杆菌中毒爆发，具有潜在的新管理选择。

Saudi Med J. 2024 Jun;45(6):626-632. doi: 10.15537/smj.2024.45.6.20240419.

Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.哺乳动物 NMJ 上的活性区结构和功能模拟预测，仅丧失钙通道不足以复制 LEMS 的作用。

J Neurophysiol. 2023 May 1;129(5):1259-1277. doi: 10.1152/jn.00404.2022. Epub 2023 Apr 19.

A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs.3,4-二氨基吡啶的高亲和力部分拮抗剂作用可介导 NMJs 动作电位增宽和递质释放增强。

J Biol Chem. 2021 Jan-Jun;296:100302. doi: 10.1016/j.jbc.2021.100302. Epub 2021 Jan 17.

Symptomatic treatment of botulism with a clinically approved small molecule.肉毒中毒的症状治疗与一种临床批准的小分子。

JCI Insight. 2020 Jan 30;5(2):132891. doi: 10.1172/jci.insight.132891.

Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A.电压门控钙通道的使用依赖性增强可挽救被 A 型肉毒神经毒素中毒的神经末梢中的神经递质传递。

Sci Rep. 2017 Nov 20;7(1):15862. doi: 10.1038/s41598-017-16064-3.

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.3,4-二氨基吡啶游离碱在 Lambert-Eaton 肌无力症患者中的群体药代动力学/药效学。

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):625-634. doi: 10.1002/psp4.12218. Epub 2017 Jul 24.

Presynaptic Deficits at Neuromuscular Junctions: A Specific Cause and Potential Target of Axonal Neuropathy in Type 2 Charcot-Marie-Tooth Disease.2型遗传性运动感觉神经病中神经肌肉接头处的突触前缺陷：轴索性神经病的特定病因和潜在靶点

J Neurosci. 2016 Aug 3;36(31):8067-9. doi: 10.1523/JNEUROSCI.1515-16.2016.

4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.4-氨基吡啶不会增强 tottering 小鼠模型的绒球小结叶功能，该模型是一种前庭小脑功能障碍和共济失调的小鼠模型。

PLoS One. 2013;8(2):e57895. doi: 10.1371/journal.pone.0057895. Epub 2013 Feb 25.

Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Lambert-Eaton 肌无力综合征治疗选择的最新进展：重点关注氨甲酰苯的使用。

Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验